Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03215030 · ClinicalTrials.gov registry record · Phase 1
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Terminated
- Registry status
- Phase 1
- Development phase
- 272
- Enrollment target
NCT03215030 is a Phase 1 study that was terminated before completion, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 272 participants.
The verdict
NCT03215030, a Phase 1 study, was terminated before completion, sponsored by Teva Branded Pharmaceutical Products R&D.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 272 participants
- Enrollment target
Study Summary
The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants. Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp alfa. Participants will receive modakafusp alfa at one of two doses which will be given through a vein.
Interventions
- DRUG Dexamethasone
- DRUG Modakafusp alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03215030
The ClinicalTrials.gov registry entry for NCT03215030 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT03215030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03215030 about?
NCT03215030 is a clinical study titled "A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma". The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2...
What is the current status of trial NCT03215030?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 272 participants. The study started on 2017-10-04. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT03215030?
The interventions under investigation include: Dexamethasone (DRUG), Modakafusp alfa (DRUG).
Who is sponsoring clinical trial NCT03215030?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.